Bure Equity AB

Latest Results (07.08.2024):

Record Year for Portfolio Companies

Bure Equity AB's latest financial results for Q4 2023 highlight a successful year for most of its portfolio companies. The four largest holdings reported record years, showcasing strong performance despite global economic challenges. This success underscores the resilience and strategic positioning of Bure's investments.

Vitrolife's Growth

In Q4 2023, Vitrolife, one of Bure Equity AB's portfolio companies, continued to grow its turnover and profit. Under the new leadership of CEO Bronwyn Brophy, who joined in August, the company has been focusing on further developing its strategy and organization, overcoming challenges in the Genetic Services business area.

XVIVO's Commercial Success

XVIVO, another key holding of Bure Equity AB, saw a 44% increase in turnover, reaching approximately SEK 600 million in Q4 2023. A notable achievement was the successful transportation and transplantation of a heart across the Atlantic, facilitated by XVIVO’s Heart Assist Transport, marking a groundbreaking milestone in medical history.

Mycronic's Revenue and Profit Growth

Mycronic, a significant portfolio company of Bure Equity AB, reported an 11% increase in turnover and a 38% rise in operating profit for Q4 2023. The Pattern Generator business area was a major contributor, with turnover up by 54% and operating profit more than doubling, reflecting a fantastic performance.

Yubico's Impressive Sales

Yubico, part of Bure Equity AB's portfolio, increased its sales by 18% to SEK 1.8 billion in Q4 2023, with an EBIT of SEK 195 million, corresponding to a margin of just over 10%. The company also went public during the year, receiving a positive reception on the stock exchange, with its share price rising by 38%.